The vaccine has been recommended by WHO for pilot introduction in selected areas of 3 African countries: Ghana,Kenya and Malawi
Kenya and Ghana to roll out Malaria vaccine after Malawi
Current estimates are that at least 360 000 children per year across the 3 pilot countries will receive the RTS,S vaccine from the health facilities where they receive their routine childhood vaccinations.
RTS,S/AS01 (RTS,S) is the world’s first malaria vaccine that has been shown to provide partial protection against malaria in young children.The vaccine acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa.
The vaccine has been recommended by WHO for pilot introduction in selected areas of 3 African countries. It will be evaluated for use as a complementary malaria control tool that could be added to (and not replace) the core package of WHO-recommended preventive, diagnostic and treatment measures.
Key Notes from WHO:
1. The vaccine offers no protection against P. vivax malaria, which predominates in many countries outside of Africa.
2. These countries included: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and the United Republic of Tanzania.
3. Severe malaria refers to those cases where the initial infection with the malaria parasite evolves into an acute, lifethreatening illness.
4. Specifically, they will evaluate the feasibility of delivering the vaccine in real-life settings, the impact of the vaccine on childhood survival and the vaccine’s safety profile in the context of routine use.
5. In 2017, malaria killed an estimated 266 000 under-fives globally.